EMA Recommends Extending Indications for Durvalumab By Ogkologos - July 17, 2025 411 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR New Research on Treating Hormone Receptor-Positive Breast Cancer From SABCS 2020 January 29, 2021 Durable Activity of Repotrectinib in Patients with ROS1 Fusion–Positive NSCLC Regardless... January 15, 2024 Savolitinib Shows Promise in Pulmonary Sarcomatoid Carcinoma and Other METex14-positive NSCLC... June 23, 2021 Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant,... September 24, 2025 Load more HOT NEWS Genetic Risk Score Increases Prediction of Severe Obesity in Adult Survivors... Study Tests Immunotherapy in People with Cancer and Autoimmune Diseases Immunotherapy treatment fast tracked to treat lung cancer patients in England Handmade Artisan Gifts For Under $30
